HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a response View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jacob, P Articles by Benowitz, N L Search for Related Content PubMed PubMed Citation Articles by Jacob, P, 3rd Articles by Benowitz, N L

Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes.

P Jacob, 3rd, L Yu, A T Shulgin and N L Benowitz

Department of Medicine, San Francisco General Hospital Medical Center, CA, USA.

OBJECTIVES: This study (1) determined levels of various tobacco alkaloids in commercial tobacco products. (2) determined urinary concentrations, urinary excretion, and half-lives of the alkaloids in humans; and (3) examined the possibility that urine concentrations of nicotine-related alkaloids can be used as biomarkers of tobacco use. METHODS: Nicotine intake from various tobacco products was determined through pharmacokinetic techniques. Correlations of nicotine intake with urinary excretion and concentrations of anabasine, anatabine, nornicotine, nicotine, and cotinine were examined. By using urinary excretion data, elimination half-lives of the alkaloids were calculated. RESULTS: Alkaloid levels in commercial tobacco products, in milligrams per gram, were as follows: nicotine, 6.5 to 17.5; nornicotine, 0.14 to 0.66; anabasine, 0.008 to 0.030; and anatabine, 0.065 to 0.27. Measurable concentrations of all alkaloids were excreted in the urine of most subjects smoking cigarettes, cigars, and pipes and using smokeless tobacco. Correlations between nicotine intake and alkaloid concentrations were good to excellent. CONCLUSIONS: Anabasine and anatabine, which are present in tobacco but not in nicotine medications, can be used to assess tobacco use in persons undergoing nicotine replacement therapy.

This article has been cited by other articles:

				J. O. Ebbert, H. H. Severson, I. T. Croghan, B. G. Danaher, and D. R. Schroeder A randomized clinical trial of nicotine lozenge for smokeless tobacco use Nicotine Tob Res, December 1, 2009; 11(12): 1415 - 1423. [Abstract] [Full Text] [PDF]

				R. D. Hurt, J. O. Ebbert, J. T. Hays, and D. D. McFadden Treating Tobacco Dependence in a Medical Setting CA Cancer J Clin, September 1, 2009; 59(5): 314 - 326. [Abstract] [Full Text] [PDF]

				N. G. Murphy, C. Albin, W. Tai, and N. L. Benowitz Anabasine Toxicity from a Topical Folk Remedy Clinical Pediatrics, September 1, 2006; 45(7): 669 - 671. [PDF]

				S. Allwright, G. Paul, B. Greiner, B. J Mullally, L. Pursell, A. Kelly, B. Bonner, M. D'Eath, B. McConnell, J. P McLaughlin, et al. Legislation for smoke-free workplaces and health of bar workers in Ireland: before and after study BMJ, November 12, 2005; 331(7525): 1117. [Abstract] [Full Text] [PDF]

				J. Hukkanen, P. Jacob III, and N. L. Benowitz Metabolism and Disposition Kinetics of Nicotine Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115. [Abstract] [Full Text] [PDF]

				S. E. Murphy, C. A. Link, J. Jensen, C. Le, S. S. Puumala, S. S. Hecht, S. G. Carmella, L. Losey, and D. K. Hatsukami A Comparison of Urinary Biomarkers of Tobacco and Carcinogen Exposure in Smokers Cancer Epidemiol. Biomarkers Prev., October 1, 2004; 13(10): 1617 - 1623. [Abstract] [Full Text] [PDF]

				P. Jacob III, D. Hatsukami, H. Severson, S. Hall, L. Yu, and N. L. Benowitz Anabasine and Anatabine as Biomarkers for Tobacco Use during Nicotine Replacement Therapy Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1668 - 1673. [Abstract] [Full Text] [PDF]

				P. G. Shields Tobacco Smoking, Harm Reduction, and Biomarkers J Natl Cancer Inst, October 2, 2002; 94(19): 1435 - 1444. [Abstract] [Full Text] [PDF]

				D. K. Miller, S. P. Sumithran, and L. P. Dwoskin Bupropion Inhibits Nicotine-Evoked [3H]Overflow from Rat Striatal Slices Preloaded with [3H]Dopamine and from Rat Hippocampal Slices Preloaded with [3H]Norepinephrine J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1113 - 1122. [Abstract] [Full Text] [PDF]

				T. P. Moyer, J. R. Charlson, R. J. Enger, L. C. Dale, J. O. Ebbert, D. R. Schroeder, and R. D. Hurt Simultaneous Analysis of Nicotine, Nicotine Metabolites, and Tobacco Alkaloids in Serum or Urine by Tandem Mass Spectrometry, with Clinically Relevant Metabolic Profiles Clin. Chem., September 1, 2002; 48(9): 1460 - 1471. [Abstract] [Full Text] [PDF]

				S. S. Hecht Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer Carcinogenesis, June 1, 2002; 23(6): 907 - 922. [Abstract] [Full Text] [PDF]

				J-F Etter and T V Perneger Measurement of self reported active exposure to cigarette smoke J Epidemiol Community Health, September 1, 2001; 55(9): 674 - 680. [Abstract] [Full Text] [PDF]